摘要
目的:评价注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(商品名:益赛普)治疗中重度寻常型银屑病患者的疗效。方法:对我院2011年1月至2014年3月,诊断为中重度寻常型银屑病患者42例,其中益赛普组20例,阿维A组22例,按银屑病面积和严重程度指数(PASI)对疗效进行评分。结果:42例患者均完成治疗,治疗12周后,益赛普组PASI30、PASI60、PASI90的比例高于阿维A组,差异具有统计学意义(<0.05)。结论:抗肿瘤坏死因子靶向治疗中重度寻常型银屑病有效。
Objective： To evaluate the effect of recombinant human tumor necrosis factor receptor（rh TNFR：Fc）in the treatment of moderate to severe plaque psoriasis on psoriasis area and severity index（PASI）. Methods：Between January 2011 and March 2014,there were 42 cases of moderate to severe plaque psoriasis patients in the Affiliated Hospital of Shihezi university school of medicine, of which there were 20 cases in trial group and 22 cases in the control group respectively, to evaluate the effect on PASI. Result： 42 cases of patients had accomplished the 12-week clinical trial. After 12 weeks the rate of PASI30、PASI60、PASI90 were significantly higher than those of the control group（P〈0.05）. Conclusion： The effect of rh TNFR-Fc is significant.
出处
《农垦医学》
2014年第4期297-299,共3页
Journal of Nongken Medicine
